Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleix Prat

Showing results (51-60 of 326) with videos related to

Pageof 33
Sort By:
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of the intrinsic molecular subtypes of breast cancerAleix Prat, Estela Pineda, Barbara Adamo, et al.
Nature Reviews. Clinical Oncology|September 13, 2024
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistanceAdrienne G Waks, Olga Martínez-Sáez, Paolo Tarantino, et al.
Cell Reports|March 12, 2014
The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitmentAdam Skibinski, Jerrica L Breindel, Aleix Prat, et al.
The Oncologist|August 22, 2014
Age-specific changes in intrinsic breast cancer subtypes: a focus on older womenEmily O Jenkins, Allison M Deal, Carey K Anders, et al.
Clinical Breast Cancer|November 9, 2021
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current EvidenceBenedetta Conte, Davide Soldato, Maria Grazia Razeti, et al.
Cancer Treatment Reviews|May 16, 2018
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancerJuan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-Martínez, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Breast Cancer Research and Treatment|June 15, 2011
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapseJ Chuck Harrell, Aleix Prat, Joel S Parker, et al.
Journal of the National Cancer Institute|August 21, 2014
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerAleix Prat, Lisa A Carey, Barbara Adamo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2009
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinibSusana Cedrés, Aleix Prat, Pablo Martínez, et al.
Pageof 33

Showing results (51-60 of 326) with videos related to

Sort By:
Pageof 33
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of the intrinsic molecular subtypes of breast cancerAleix Prat, Estela Pineda, Barbara Adamo, et al.
Nature Reviews. Clinical Oncology|September 13, 2024
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistanceAdrienne G Waks, Olga Martínez-Sáez, Paolo Tarantino, et al.
Cell Reports|March 12, 2014
The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitmentAdam Skibinski, Jerrica L Breindel, Aleix Prat, et al.
The Oncologist|August 22, 2014
Age-specific changes in intrinsic breast cancer subtypes: a focus on older womenEmily O Jenkins, Allison M Deal, Carey K Anders, et al.
Clinical Breast Cancer|November 9, 2021
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current EvidenceBenedetta Conte, Davide Soldato, Maria Grazia Razeti, et al.
Cancer Treatment Reviews|May 16, 2018
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancerJuan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-Martínez, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Breast Cancer Research and Treatment|June 15, 2011
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapseJ Chuck Harrell, Aleix Prat, Joel S Parker, et al.
Journal of the National Cancer Institute|August 21, 2014
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerAleix Prat, Lisa A Carey, Barbara Adamo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2009
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinibSusana Cedrés, Aleix Prat, Pablo Martínez, et al.
Pageof 33